Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180669 · ClinicalTrials.gov registry record · NA
Reward-based Technology to Improve OUD Treatment
A NA study, sponsored by Q2i.
- Terminated
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT05180669: Clinical Trial NA study, sponsored by Q2i.
NCT05180669 is a NA study that was terminated before completion, run by Q2i. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05180669, a NA study, was terminated before completion, sponsored by Q2i.
- TERMINATED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This project will utilize a digital mobile platform, Opioid Addiction Recovery Support with contingency management (OARSCM), to increase MAT treatment initiation and adherence among OUD patients recruited from emergency departments and inpatient acute care.
Primary Outcome
Percentage of patients who schedule an outpatient Suboxone intake prior to discharge from acute care
Interventions
- OTHER OARSCM Software Application
- OTHER MyMAT Software Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2025-05-31 |
| Phase | NA |
Why NCT05180669 stopped before completion
NCT05180669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which OARSCM Software Application is the first listed.
NCT05180669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05180669 about?
NCT05180669 is a clinical study titled "Reward-based Technology to Improve OUD Treatment". Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This project will utilize a digital ...
What is the current status of trial NCT05180669?
This trial is currently terminated. It is a NA study. The enrollment target is 41 participants. The study started on 2022-11-18. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT05180669?
The interventions under investigation include: OARSCM Software Application (OTHER), MyMAT Software Application (OTHER).
Who is sponsoring clinical trial NCT05180669?
This trial is sponsored by Q2i, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05180669's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI